Shots:

• The ongoing P-II/III CAPELLA trial evaluating the antiviral activity of lenacapavir (SC- every 6mos.) + other antiretroviral agents vs PBO in 36 patients in a ratio (2:1) with multi-drug resistant HIV-1 infection. The trial is being conducted at research centers in North America- the EU & Asia
• The study demonstrated high rates of virologic suppression @26wks.- viral load reduction from baseline of at least 0.5 log10 copies/mL for 14 days functional monothx. period (88% vs 17%)- 81% of patients achieved an undetectable viral load- was generally well tolerated with no AEs
• If approved- the therapy will be the 1st capsid inhibitor & the only HIV-1 treatment option administered every 6mos.

  Ref: Gilead | Image: Gilead